Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 chemoradiotherapy study for primary intracranial germ cell tumors
jRCTs031180223Phase 2Recruiting
- Sponsor
- Gold Ribbon Network
- Start
- Jan 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of carboplatin, etoposide, ifosfamide and cisplatin in intracranial germ cell tumor (ICGCT) (3 arms), sponsored by Gold Ribbon Network. Primary endpoint: 5-year progression-free survival. Started Jan 2011; status: recruiting.
02
Drugs
carboplatinetoposideifosfamidecisplatin
03
Conditions
intracranial germ cell tumor (ICGCT)
Beyond the preview
Go deeper on jRCTs031180223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180223.